X4 Pharmaceuticals announces presentations at the ASH Annual Meeting on mavorixafor for chronic neutropenia treatment.
Quiver AI Summary
X4 Pharmaceuticals announced its participation in the 66th American Society of Hematology (ASH) Annual Meeting, set to take place from December 7-10, 2024, in San Diego, CA. The company will present a trial-in-progress poster regarding its pivotal Phase 3 clinical trial of mavorixafor, an oral CXCR4 antagonist, aimed at treating chronic neutropenia (CN). The trial, named 4WARD, is designed to evaluate the efficacy, safety, and tolerability of mavorixafor in patients experiencing recurrent infections and seeks to enroll 150 participants globally. X4's CEO, Dr. Paula Ragan, expressed excitement about the trial, highlighting the lack of treatment innovation in CN for nearly three decades. The company will also host booth #2106 to provide further information about the trial and will deliver an oral presentation on preclinical data related to CXCR4 antagonism's effects on neutropenia.
Potential Positives
- X4 Pharmaceuticals is presenting a trial-in-progress poster at the prestigious 66th American Society of Hematology Annual Meeting, highlighting its ongoing pivotal Phase 3 clinical trial for mavorixafor, indicating active advancements in their research efforts.
- The Phase 3 trial aims to address chronic neutropenia, a condition that has seen no treatment innovation in nearly 30 years, positioning X4 as a potential leader in novel therapeutic options for this underserved patient population.
- By sharing preclinical data on mavorixafor's effectiveness at the ASH meeting, X4 Pharmaceuticals is strengthening its scientific credibility and engaging with key clinicians, which could foster professional relationships and future collaborations.
- The global scope of the 4WARD trial, with plans to enroll participants across multiple countries, demonstrates X4's commitment to developing therapies that can meet diverse patient needs worldwide.
Potential Negatives
- Long timeline for the Phase 3 clinical trial (52 weeks) may delay potential market entry for mavorixafor, impacting financial forecasts and investor sentiment.
- The company indicates that recruiting patients for the trial is ongoing, which can signal difficulties in patient enrollment or interest in the study.
- There's potential for investor concern as the chronic neutropenia community has not seen treatment innovations for nearly 30 years, indicating high stakes for the trial's success.
FAQ
What is the 4WARD clinical trial by X4 Pharmaceuticals?
The 4WARD trial is a pivotal Phase 3 study evaluating mavorixafor for chronic neutropenia, assessing its efficacy and safety.
When and where will X4 Pharmaceuticals present at ASH 2024?
X4 will present at the ASH Annual Meeting in San Diego, CA, from December 7-10, 2024.
What is mavorixafor and its significance?
Mavorixafor is an oral CXCR4 antagonist aimed at treating chronic neutropenia, offering a potential alternative to injectable G-CSF.
How many participants are being enrolled in the 4WARD trial?
The trial aims to enroll 150 participants across 90 to 110 sites in 20 to 25 countries.
What are the main goals of the 4WARD trial?
The main goals are to evaluate the annualized infection rate and positive ANC response in participants with chronic neutropenia.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$XFOR Insider Trading Activity
$XFOR insiders have traded $XFOR stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $XFOR stock by insiders over the last 6 months:
- PAULA RAGAN (President and CEO) has traded it 3 times. They made 0 purchases and 3 sales, selling 303,230 shares.
- MARK BALDRY (Chief Commercial Officer) sold 11,127 shares.
- MARY DIBIASE (Chief Operating Officer) has traded it 2 times. They made 0 purchases and 2 sales, selling 70,337 shares.
- ARTHUR TAVERAS (Chief Scientific Officer) sold 76,920 shares.
- ADAM S. MOSTAFA (Chief Financial Officer) sold 230,645 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$XFOR Hedge Fund Activity
We have seen 48 institutional investors add shares of $XFOR stock to their portfolio, and 40 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 4,051,000 shares (-100.0%) from their portfolio in Q3 2024
- AVIDITY PARTNERS MANAGEMENT LP removed 2,413,000 shares (-100.0%) from their portfolio in Q2 2024
- PALE FIRE CAPITAL SE added 1,425,760 shares (+805.4%) to their portfolio in Q3 2024
- SIO CAPITAL MANAGEMENT, LLC removed 1,196,292 shares (-47.9%) from their portfolio in Q3 2024
- VELAN CAPITAL INVESTMENT MANAGEMENT LP removed 659,020 shares (-100.0%) from their portfolio in Q3 2024
- SCHONFELD STRATEGIC ADVISORS LLC added 651,107 shares (+51.3%) to their portfolio in Q3 2024
- PROPEL BIO MANAGEMENT, LLC removed 535,000 shares (-100.0%) from their portfolio in Q2 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BOSTON, Dec. 04, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced its upcoming presentations at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, including a trial-in-progress poster on the ongoing pivotal Phase 3 clinical trial exploring the use of mavorixafor, an oral CXCR4 antagonist, for the treatment of people with chronic neutropenia (CN). The meeting will take place December 7-10, 2024, in San Diego, CA.
“We’re pleased to be sharing details of our ongoing Phase 3 clinical trial at ASH as we continue to recruit patients and activate study sites across the globe. The initiation of this trial was a significant milestone for the chronic neutropenia community that – unfortunately – hasn’t seen any treatment innovation in nearly 30 years,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. “We look forward to connecting with clinicians at the ASH meeting and sharing more about our vision for mavorixafor as an oral option for the treatment of CN that could potentially reduce or replace the use of injectable G-CSF.”
The Phase 3 4WARD trial is evaluating the efficacy, safety, and tolerability of oral, once-daily mavorixafor (with or without stable doses of injectable G-CSF) in people with congenital, acquired primary autoimmune or acquired primary idiopathic CN who are experiencing recurrent and/or serious infections. The 52-week trial is a randomized, double-blind, placebo-controlled, multicenter study aiming to enroll 150 participants across 90 to 110 sites in 20 to 25 countries.
X4 will also be hosting a booth (#2106) at the conference to share information about the ongoing 4WARD clinical trial.
Additionally, in an oral presentation at the meeting, the company will present preclinical data on the potential for CXCR4 antagonism to correct peripheral blood neutropenia and bone marrow neutrophil accumulation caused by a loss-of-function in the CXCR2 pathway.
|
Poster Presentation Details:
|
|
| Title: “Trials in Progress: A Phase 3 Study to Investigate Efficacy, Safety, and Tolerability of Mavorixafor in Participants with Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders” | |
| Number: 3924.1 | |
| Date and Time: Monday, December 9, 2024: 6:00-8:00 p.m. PST | |
| Location: Manchester Grand Hyatt San Diego, Halls G-H | |
|
Oral Presentation Details:
|
|
| Title: “ CXCR4 Antagonism Corrects Peripheral Neutropenia and Mature Neutrophil Accumulation in Bone Marrow in a Pharmacological Mouse Model of CXCR2 Loss-of-Function” | |
| Number: 418 | |
| Date and Time: Sunday, December 8, 2024: 10:15 a.m. PST | |
| Location: Manchester Grand Hyatt San Diego, Grand Hall D | |
About the 4WARD Global, Pivotal, Phase 3 Clinical Trial
The 4WARD trial is a global, pivotal Phase 3 clinical trial (
NCT06056297
) evaluating the efficacy, safety, and tolerability of oral, once-daily mavorixafor (with or without G-CSF) in people with congenital, acquired primary autoimmune or acquired primary idiopathic chronic neutropenia who are experiencing recurrent and/or serious infections. The 52-week trial is a randomized, double-blind, placebo-controlled, multicenter study aiming to enroll 150 participants with confirmed trough ANC levels less than 1,500 cells per microliter at baseline screening and histories of two or more serious and/or recurrent infections in the prior year. The primary endpoint of the trial is based on two outcome measures: annualized infection rate and positive ANC response.
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI® (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at
www.x4pharma.com
.
Company Contact:
José Juves
Head of Corporate & Patient Affairs
[email protected]
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
[email protected]
(617) 430-7576
